CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
inofolic combi +1 moredrug
Likely dose
Glucophage 500Mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05951309
NCT05951309N/ACompleted
CompareCT.gov

Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients

Near East University, Turkey·interventional·Posted Jul 19, 2023·Updated Jul 19, 2023

In Brief

A clinical study evaluating inofolic combi and Glucophage 500Mg Tablet for PCOS and Insulin Resistance. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Policystic ovary syndrome is the most common endocrinopthy during reproductive period. One of the factors implicated in the pathogenesis is insulin resistance. Asprosin, which is secreted from white adipose tissue is a new candidate for insulin resistance. Myoinositol is known to reduce insulin resistance in PCOS patients. The effect of myoinsitol on serum asprosin levels is unknown yet. This study aimed to evaluate the effect of myoinositol on serum asprosin levels in PCOS patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPCOS, Insulin Resistance
CountriesCyprus
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJul 19, 2023
Enrollment StartSep 1, 2021
Primary CompletionSep 30, 2022
Study CompletionJun 3, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.0 years ago

Interventions

inofolic combidrug

The patients in this group were given inofolic combi once a day for 12-16 weeks

Glucophage 500Mg Tabletdrug

The patients in this group were given glucophage three times a day for 12-16 weeks